Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Alzheimer's disease Therapeutics Market. LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- DelveInsight's“Acute Respiratory Distress Synd ...

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...

Eli Lilly has followed through on its plan to file for approval of its Alzheimer's disease candidate donanemab, and is planning to take on Biogen and Eisai with a head-to-head trial against their ...

People who are newly diagnosed with Alzheimer’s and their caregivers need more support in navigating the healthcare system.

Philippa Salter, Managing Neurology Analyst at GlobalData, said that Eisai/Biogen’s Leqembi (lecanemab) and Eli Lilly’s ...

Eli Lilly recently updated Q4 revenue guidance, and sales are expected to come in lower than previously anticipated. While this could suggest the company is experiencing sluggish or plateauing ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...